Lack of association between the Thr431Asn and Arg83Lys polymorphisms of the ROCK2 gene and diabetic retinopathy

Current Eye Research

Volumn 35, Issue 12, 2010, Pages 1128-1134

  Demiryurek, Abdullah T ^a   Erbagci, Ibrahim ^a   Oztuzcu, Serdar ^a   Alasehirli, Belgin ^a   Ozkara, Esma ^a   Seker, Mehmet ^b   Snmez, Ayhan ^b   Ozsan, Muge ^a   Camci, Celalettin ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b AMERICAN HOSPITAL   (Turkey)

Author keywords

Diabetic retinopathy; Genetic polymorphisms; Haplotype analysis; Rho kinase; ROCK2

Indexed keywords

GENOMIC DNA; RHO KINASE; RHO KINASE 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; AMINO ACIDS; DIABETIC RETINOPATHY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RHO-ASSOCIATED KINASES; TURKEY;

EID: 78649733296     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2010.507903     Document Type: Article

References (44)

1. Donaghue KC, Chiarelli F, Trotta D, et al. Microvascular and macrovascular complications associated with diabetes in children and adolescents. Pediatr Diabetes. 2009;10(Suppl 12):195-203.
2. Frank RN. Diabetic retinopathy. N Engl J Med. 2004;350:48-58.
3. Aylward GW. Progressive changes in diabetics and their management. Eye (Lond). 2005;19:1115-1118.
4. Fong DS, Aiello LP, Ferris FL 3rd, et al. Diabetic retinopathy. Diabetes Care. 2004;27:2540-2553.
5. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: A systematic review. JAMA. 2007;298:902-916.
6. Sapieha P, Hamel D, Shao Z, et al. Proliferative retinopathies: Angiogenesis that blinds. Int J Biochem Cell Biol. 2010;42:5-12.
7. Pastor JC, de la, Rúa ER, Martín F Proliferative vitreoretinopathy: Risk factors and pathobiology Prog Retin Eye Res. 2002;21:127-144.
8. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Pathol. 1995;146:1029-1039.
9. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev. 2004;25:581-611. (Pubitemid 39099316)
10. Yokota T, Utsunomiya K, Taniguchi K, et al. Involvement of the Rho/Rho kinase signaling pathway in platelet-derived growth factor BB-induced vascular endothelial growth factor expression in diabetic rat retina. Jpn J Ophthalmol. 2007;51:424-430.
11. Jin HG, Yamashita H, Nagano Y, et al. Hypoxia-induced upregulation of endothelial small G protein RhoA and Rho-kinase/ROCK2 inhibits eNOS expression. Neurosci Lett. 2006;408:62-67.
12. Schmandke A, Schmandke A, Strittmatter SM. ROCK and Rho: Biochemistry and neuronal functions of Rho-associated protein kinases. Neuroscientist. 2007;13:454-469.
13. Shi J, Wei L. Rho kinase in the regulation of cell death and survival. Arch Immunol Ther Exp (Warsz). 2007;55:61-75.
14. Furukawa N, Ongusaha P, Jahng WJ, et al. Role of Rhokinase in regulation of insulin action and glucose homeostasis. Cell Metab. 2005;2:119-129.
15. Arita R, Hata Y, Nakao S, et al. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage. Diabetes. 2009;58:215-226.
16. Shimizu Y, Thumkeo D, Keel J, et al. ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol. 2005;168:941-953.
17. Thumkeo D, Keel J, Ishizaki T, et al. Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol Cell Biol. 2003;23:5043-5055.
18. Thumkeo D, Shimizu Y, Sakamoto S, et al. ROCK-I and ROCK-II cooperatively regulate closure of eyelid and ventral body wall in mouse embryo. Genes Cells. 2005;10:825-834.
19. Liew G, Klein R, Wong TY. The role of genetics in susceptibility to diabetic retinopathy Int Ophthalmol Clin. 2009;49:35-52.
20. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
21. Kalender ME, Demiryürek S, Oztuzcu S, et al. Association between the Thr431Asn polymorphism of the ROCK2 gene and risk of developing metastases of breast cancer. Oncol Res. 2010 18:583-591.
22. Yamaguchi H, Kasa M, Amano M, et al. Molecular mechanism for the regulation of Rho-kinase by dimerization and its inhibition by fasudil. Structure. 2006;14:589-600.
23. Doran JD, Liu X, Taslimi P, et al. New insights into the structure-function relationships of Rho-associated kinase: A thermodynamic and hydrodynamic study of the dimer-to-monomer transition and its kinetic implications. Biochem J. 2004;384:255-262.
24. Seasholtz TM, Wessel J, Rao F, et al. Rho kinase polymorphism infuences blood pressure and systemic vascular resistance in human twins: Role of heredity Hypertension. 2006;47:937-947.
25. Zhao Q, Wang L, Yang W, et al. Interactions among genetic variants from contractile pathway of vascular smooth muscle cell in essential hypertension susceptibility of Chinese Han population. Pharmacogenet Genomics. 2008;18:459-466.
26. Peterson H, Laivuori H, Kerkelä E, et al. ROCK2 allelic vari-ants are not associated with pre-eclampsia susceptibility in the Finnish population. Mol Hum Reprod. 2009;15:443-449.
27. Schröder S, Palinski W, Schmid-Schönbein GW. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy Am J Pathol. 1991;139:81-100.
28. Joussen AM, Murata T, Tsujikawa A, et al. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol. 2001;158:147-152.
29. Laufs U, Liao JK. Post-transcriptional regulation of endothe-lial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998;273:24266-24271.
30. Ming XF, Viswambharan H, Barandier C, et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of pro-tein kinase B/Akt in human endothelial cells. Mol Cell Biol. 2002;22:8467-8477.
31. Higashi M, Shimokawa H, Hattori T, et al. Long-term inhibi-tion of Rho-kinase suppresses angiotensin II-induced cardio-vascular hypertrophy in rats in vivo: Effect on endothelial NAD(P)H oxidase system. Circ Res. 2003;93:767-775.
32. Shiotani S, Shimada M, Taketomi A, et al. Rho-kinase as a novel gene therapeutic target in treatment of cold isch-emia/reperfusion-induced acute lethal liver injury: Effect on hepatocellular NADPH oxidase system. Gene Ther. 2007;14:1425-1433.
33. Satoh S, Ikegaki I, Suzuki Y, et al. Neuroprotective prop-erties of a protein kinase inhibitor against ischaemia-in-duced neuronal damage in rats and gerbils. Br J Pharmacol. 1996;118:1592-1596.
34. Iwasaki H, Okamoto R, Kato S, et al. High glucose induces plasminogen activator inhibitor-1 expression through Rho/Rho-kinase-mediated NF-kappaB activation in bovine aortic endothelial cells. Atherosclerosis. 2008;196:22-28.
35. Begum N, Duddy N, Sandu O, et al. Regulation of myosin-bound protein phosphatase by insulin in vascular smooth muscle cells: Evaluation of the role of Rho kinase and phos-phatidylinositol-3-kinase-dependent signaling pathways. Mol Endocrinol. 2000;14:1365-1376.
36. Koga T, Koga T, Awai M, et al. Rho-associated protein kinase inhibitor, Y-27632, induces alterations in adhesion, contrac-tion and motility in cultured human trabecular meshwork cells. Exp Eye Res. 2006;82:362-370.
37. Rao VP, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. Bio Drugs. 2007;21:167-177.
38. Tanihara H, Inatani M, Honjo M, et al. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol. 2008;126:309-315.
39. Lingor P, Teusch N, Schwarz K, et al. Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sul-phate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo. J Neurochem. 2007;103:181-189.
40. Lingor P, Tönges L, Pieper N, et al. ROCK inhibition and CNTF interact on intrinsic signalling pathways and differ-entially regulate survival and regeneration in retinal gan-glion cells. Brain. 2008;131:250-263.
41. Hirata A, Inatani M, Inomata Y, et al. Y-27632, a Rho-associated protein kinase inhibitor, attenuates neuronal cell death after transient retinal ischemia. Graefes Arch Clin Exp Ophthalmol. 2008;246:51-59.
42. Hata Y, Miura M, Nakao S, et al. Antiangiogenic properties of fasudil, a potent Rho-Kinase inhibitor Jpn J Ophthalmol. 2008;52:16-23.
43. Patz A. Studies on retinal neovascularization. Invest Ophthalmol Vis Sci. 1980;19:1133-1138.
44. Honjo M, Tanihara H, Kameda T, et al. Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma fltration surgery. Invest Ophthalmol Vis Sci. 2007;48:5549-5557.